论文部分内容阅读
目的分析及正确评估氟喹诺酮类联合一线抗痨方案在治疗耐药结核病(MDR-PTB)的效果。方法将2003年6月～2007年6月200例MDR-PTB病人随机分为含氟喹诺酮类药治疗组Ⅰ组及不使用氟喹诺酮类药对照组Ⅱ组,疗程为18个月。结果Ⅰ组病人100例92例完成疗程,痰菌阴转86例(93%),Ⅱ组100例96例完成疗程,痰菌阴转49例(52%),痰菌阴转治疗组明显高于对照组(P<0.05),病灶吸收及空洞闭合Ⅰ组病人均优于Ⅱ组。结论含氟喹诺酮类药抗痨方案治疗MDR-PTB效果明显。
Objective To analyze and correctly evaluate the efficacy of fluoroquinolone combined with first-line anti-tuberculosis in the treatment of drug-resistant tuberculosis (MDR-PTB). Methods 200 cases of MDR-PTB from June 2003 to June 2007 were randomly divided into group Ⅰ with fluoroquinolone treatment and group Ⅱ with no treatment with fluoroquinolone. The course of treatment was 18 months. Results Of the 100 patients in group Ⅰ, 92 patients completed the treatment course, 86 patients (93%) had sputum negative conversion, 96 patients completed the treatment in group Ⅱ, 49 patients (52%) had sputum negative conversion, and the sputum negative conversion rate was significantly higher In the control group (P <0.05), the patients in group Ⅰ with lesion absorption and empty closure were superior to group Ⅱ. Conclusion Fluoroquinolone anti-tuberculosis treatment of MDR-PTB obvious effect.